RESUMEN
BACKGROUND: BK virus (BKV)-associated nephropathy is definitely involved in allograft failure after kidney transplant. Thus, the need for an early control of viral reactivation in immunocompromised patients is well established. Determination of urinary release of decoy cells (DC) and BK viral load in plasma and urine by polymerase chain reaction (PCR) usually precedes renal biopsy. The aim of the study is to assess viral reactivation by BKV-DNA PCR and DC detection in urinary sediment using automated intelligent microscopy. METHODS: Seventy-eight kidney transplant patients were analyzed for the presence of plasma BKV-DNA by quantitative TaqMan real-time PCR. Additionally, automated intelligent microscopy was used for urine sediment analysis, allowing to count cells with decoy feature, confirmed by phase contrast microscopic review. RESULTS: Plasma BKV-DNA PCR was detected in 14 (17.9%) patients. DC were identified in 19 (24.3%) urine sediments by automated analyzers and confirmed by microscopic observation. Two patients were BKV-DNA-positive/DC-negative; conversely, 7 subjects were DC-positive/BKV-DNA-negative. CONCLUSIONS: Plasma quantification of BK viral load is currently the best noninvasive method for the detection of viral reactivation. Nevertheless, automated methods to screen for the presence of DC in urine could facilitate early BK virus replication diagnosis and patient follow-up by quantitative and visual results.
Asunto(s)
Enfermedades Renales/orina , Trasplante de Riñón , Microscopía/métodos , Infecciones por Polyomavirus/orina , Infecciones Tumorales por Virus/orina , Adulto , Virus BK , ADN Viral/sangre , Femenino , Humanos , Interpretación de Imagen Asistida por Computador/instrumentación , Interpretación de Imagen Asistida por Computador/métodos , Huésped Inmunocomprometido , Enfermedades Renales/diagnóstico , Enfermedades Renales/virología , Masculino , Microscopía/instrumentación , Persona de Mediana Edad , Infecciones por Polyomavirus/diagnóstico , Infecciones por Polyomavirus/inmunología , Reacción en Cadena en Tiempo Real de la Polimerasa , Trasplante Homólogo , Infecciones Tumorales por Virus/diagnóstico , Infecciones Tumorales por Virus/inmunología , Urinálisis/instrumentación , Urinálisis/métodosRESUMEN
The Alström syndrome is a rare genetic disorder, inherited in an autosomal recessive manner. It has recently been classified as a ciliopathic disorder. Alström syndrome is a multiorgan pathology characterized by cone-rod dystrophy, hearing loss, childhood truncal obesity, insulin resistance and hyperinsulinemia, type 2 diabetes mellitus, dyslipidemia, short stature in adulthood, hypothyroidism, hypogonadism, dilated or restrictive cardiomyopathy, and progressive pulmonary, hepatic, and renal dysfunction. End-stage renal disease can occur as early as the late teens and is the leading cause of death. More than 900 people with Alström syndrome have been reported worldwide. We present a case of a 42-year-old man affected by this syndrome with end-stage renal disease, type 2 diabetes mellitus, and loss of visual function and hearing who received a kidney transplant from a cadaveric donor. Basiliximab and steroid were used as induction therapy. Tacrolimus, mycophenolate mofetil, and steroid were used as maintenance therapy. No complications were reported during the recovery. In selected patients affected by Alström syndrome, renal transplantation can be a successful treatment for chronic kidney disease.
Asunto(s)
Síndrome de Alstrom/complicaciones , Fallo Renal Crónico/etiología , Fallo Renal Crónico/cirugía , Trasplante de Riñón , Adulto , Humanos , MasculinoRESUMEN
INTRODUCTION: Immunosuppressive protocols containing everolimus (EVR) preserve good renal function in kidney transplantation (KT), although they are often complicated by several adverse events. We have evaluated the efficacy and safety of a protocol with late (1 month after KT) EVR introduction. MATERIAL AND METHODS: This study randomized 49 de novo patients undergoing KT between September 2012 and June 2014 into 2 groups: group A (n = 24) with late EVR introduction and tacrolimus reduction, and group B (control group; n = 25) with a standard immunosuppressive regimen. Primary aims were 1-year patient and graft survivals and acute rejection rates. Secondary aims were related to wound, metabolic, and hematologic complications. RESULTS: Patient and graft survivals were similar in both groups. One year after KT, median serum creatinine was inferior in group A (1.4 vs 1.8 mg/dL; P = .004). Late acute rejection (8.3 vs 12.0%; P = 1.0) and wound complication (4.2 vs 4.0%; P = 1.0) rates were similar. Higher cholesterol and triglycerides and lower platelets and hemoglobin levels were observed in group A. CONCLUSIONS: In our experience, delayed introduction of EVR shows similar results with respect to its early introduction, contemporaneously presenting fewer wound complications and lymphoceles. A higher rate of metabolic and hematologic complications are, however, observed in patients under EVR therapy. Further multicenter studies should be performed to confirm these preliminary results.
Asunto(s)
Everolimus/administración & dosificación , Supervivencia de Injerto/efectos de los fármacos , Inmunosupresores/administración & dosificación , Trasplante de Riñón/efectos adversos , Complicaciones Posoperatorias/sangre , Adulto , Anciano , Relación Dosis-Respuesta a Droga , Femenino , Rechazo de Injerto/epidemiología , Humanos , Pruebas de Función Renal , Masculino , Persona de Mediana Edad , Tacrolimus/administración & dosificación , Factores de Tiempo , Resultado del TratamientoRESUMEN
it is difficult to diagnose because of its nonspecific presentation. This condition frequently occurs in association with an extreme physical stress and may lead to acute adrenal insufficiency or death if not promptly and properly treated. We report a rare case of acute bilateral adrenal hemorrhage with adrenal insufficiency following duodenopancreatectomy for ampulloma in absence of surgical complications. Early diagnosis and corticosteroid replacement with aggressive management of the precipitating pathology are essential to enable a successful outcome.
Asunto(s)
Enfermedades de las Glándulas Suprarrenales/etiología , Hemorragia/etiología , Pancreaticoduodenectomía/efectos adversos , Insuficiencia Suprarrenal/etiología , Humanos , Complicaciones PosoperatoriasRESUMEN
Use of expanded criteria donors (ECD) has increased worldwide in previous years because of the donor scarcity. However, ECD are related to a greater risk of complications and shorter graft longevity. Delayed graft function (DGF) which impacts renal graft survival, represents one of the most common complications posttransplantation. The purpose of this study was to analyse DGF incidence among ECD kidneys and its role on early and intermediate recipient and graft survivals. We prospectively analyzed 46 ECD cases divided as group A (absence of DGF; n = 23) and B (DGF; n = 23). Group B was composed of older donors (P = .033) with longer cold ischemia times (P = .017), and greater incidences of acute rejection episodes (ARE) (P < .0001). Comparing group A with group B, we observed 1-year and 3-year overall recipient survivals to be 95.7% and 95.7% versus 91.3% and 91.3%, respectively (P = not significant). Censored 1-year and 3-year overall graft survivals were 100% and 92.9% versus 85.6% and 79.9%, respectively (P = .026). Analyzing the patients with DGF without (n = 9) versus with concomitant ARE (n = 14), no differences were noted in recipient and graft survivals. The incidence of DGF was strictly related to increased donor age, greater cold ischemia time, and presence of an ARE while DGF did not have a role in recipient survival, it reduced, graft survival. Concomitant ARE was not related to an impaired graft function.
Asunto(s)
Funcionamiento Retardado del Injerto/epidemiología , Trasplante de Riñón/mortalidad , Complicaciones Posoperatorias/epidemiología , Donantes de Tejidos , Adulto , Anciano , Cadáver , Funcionamiento Retardado del Injerto/etiología , Femenino , Rechazo de Injerto/epidemiología , Rechazo de Injerto/etiología , Humanos , Italia/epidemiología , Trasplante de Riñón/normas , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Análisis de SupervivenciaRESUMEN
In patients with end-stage chronic kidney disease (CKD) and type 1 diabetes mellitus (DM 1), simultaneous pancreas-kidney (SPK) transplantation is currently considered the gold standard therapy. The aim of this study was to analyze and report the long-term clinical outcomes of the 23 SPK transplantations performed at our institution over an 84-month period (January 1, 2000 to December 31, 2006). A prospective analysis of these patients included donor, recipient, and transplantation characteristics. The only requirements for transplantation were blood group compatibility and a negative cross-match. Bladder drainage via pancreaticoduodenocystostomy was performed in all of the patients. Due to a pulmonary embolus 1 patient (4.3%) died at 2 months. The actuarial patient survival rates at 3 months and 1, 3, and 5 years were 95.6%. Causes for the renal graft loss were chronic allograft nephropathy in 3 cases (13%) and death of the patient in 1 case (4.3%). The actuarial censored renal allograft survival rates at 3 months and at 1 year were 100%, and at 3 and 5 years were 91.3%. Causes for the renal graft loss were chronic rejection in 1 case (4.3%) and patient death in 1 case (4.3%). The actuarial censored pancreatic allograft survival rates at 3 months and at 1 and 3 years were 100%, and at 5 years was 95.6%. The results of this work add further evidence that SPK is the gold standard therapy for selected patients with end-stage CKD due to DM 1.
Asunto(s)
Diabetes Mellitus Tipo 1/cirugía , Nefropatías Diabéticas/cirugía , Fallo Renal Crónico/cirugía , Trasplante de Riñón/estadística & datos numéricos , Trasplante de Páncreas/estadística & datos numéricos , Adolescente , Adulto , Glucemia/metabolismo , Femenino , Estudios de Seguimiento , Supervivencia de Injerto , Humanos , Fallo Renal Crónico/etiología , Trasplante de Riñón/mortalidad , Masculino , Persona de Mediana Edad , Trasplante de Páncreas/mortalidad , Estudios Prospectivos , Estudios Retrospectivos , Análisis de SupervivenciaRESUMEN
Hepatocellular carcinoma (HCC) is considered an optimal indication for liver transplantation (LT) because it may eliminate both the tumor and the underlying liver disease. The present study sought to compare cumulative survival, rate of HCC recurrence, and causes of death among patients with cirrhosis and HCC before and after the adoption of more restrictive criteria (Milan selection criteria) at the time of patient listing. Among 226 adult patients who received an elective liver transplantation between 1999 and 2005, 58 (27%) had a diagnosis of HCC at the time. The 38 patients who underwent transplantation for HCC in the period 1989 to 1998 were considered the "historical group." After LT (mean follow-up, 34 + 28 months), the cumulative survival rate was better among HCC versus non-HCC recipients (93% vs 71% at 1 year and 81% vs 67% at 3 years, respectively; P < .046), although the difference tended to attenuate after 5 years (66% vs 67%, respectively). Tumor recurrence (evaluated in patients surviving at least 3 months after LT) was observed in 10/31 in the historical group versus 4/53 among those who underwent transplantation after 1999. Among the causes of death, recurrence represented 50% in the old series and 23% in patients who underwent transplantation after 1999. Cumulative survival significantly improved among HCC patients who underwent transplantation after 1999 (93% vs 66% at 1 year and 81% vs 50% at 3 years; P < .00001). The 58 patients who underwent transplantation with a diagnosis of cirrhosis and concomitant HCC after 1999 showed even better survival than patients who underwent transplantation for end-stage liver disease without malignancy.
Asunto(s)
Carcinoma Hepatocelular/cirugía , Cirrosis Hepática/cirugía , Trasplante de Hígado/fisiología , Adulto , Carcinoma Hepatocelular/mortalidad , Humanos , Cirrosis Hepática/mortalidad , Trasplante de Hígado/mortalidad , Persona de Mediana Edad , Análisis de Supervivencia , Resultado del TratamientoRESUMEN
The incidence of hemangiomas is 2-7% in the general population. We evaluated more than 300 patients with hepatic hemangiomas. Surgical removal of hepatic hemangiomas was performed in 48 cases due to uncertain diagnosis (2 cases), intractable symptoms (26 cases), size increase (18 cases), and liver failure in 2 cases that were treated by hepatic transplantation. In all, 26 patients underwent enucleation of hemangiomas or segmentectomies, while the remaining 20 patients underwent right lobectomies or left lateral segmentectomies. Blood transfusions were required in four cases (including two liver transplants); mean post-resection hospital stay was 6.3 days. We observed no perioperative mortality and only two cases of major morbidity (bile leaks not requiring reoperation). Our experience confirms that, after adequate patient selection, surgical treatment of hepatic hemangiomas is a very effective therapeutic choice with no mortality and low morbidity.
RESUMEN
BACKGROUND: Transplantation from living donors, in Italy, is still not accepted, in particular those from unrelated donors. The aim of this paper was to present the experience of one transplant center. MATERIALS AND METHODS: Since 1982, 608 transplants were performed from living donors using cyclosporine as the main component of immunosuppressive therapy. Among those, 402 transplants were from related living donors (338 one haplotype pairs and 25 zero haplotypes pairs) and 206 from unrelated living donors (171 spouses and 35 emotionally related subjects). RESULTS: Graft survival at 1, 5, and 10 years showed no statistically meaningful difference between the two groups. A group of 19 transplants performed in predialytic phase patients was compared with a contemporaneous group of 167 transplants performed in patients who were already receiving dialysis. These two groups did not show any statistically meaningful difference in graft survival at 1, 5, or 10 years. DISCUSSION AND CONCLUSIONS: We think that transplants from living donors, whether related or unrelated, must always be proposed as a therapeutic option for end-stage renal disease patients, since they show an higher graft survival than that from cadaveric donors, independent of the compatibility between donor and recipient and independent of the degree of relationship of the pair. Transplantation from living donors definitely is a complementary, not substitutive, program to that from cadaveric donors, which should always be encouraged with awareness campaigns among the population and targeted programs for healthy personnel.
Asunto(s)
Supervivencia de Injerto/fisiología , Trasplante de Riñón/mortalidad , Donadores Vivos , Análisis Actuarial , Femenino , Humanos , Fallo Renal Crónico/mortalidad , Fallo Renal Crónico/cirugía , Masculino , Estudios Retrospectivos , Esposos , Análisis de SupervivenciaRESUMEN
Putrescine, spermidine and spermine are polyamines deriving from ornithine. These are vital molecules for cell duplication processes; in fact, enzyme inhibitors responsible for synthesis are able to block cell multiplication. It is interesting to observe that there is an increased concentration of the polyamines and enzymes responsible for synthesis in solid tumours in man and in biological fluids in subjects carrying tumours. The authors assayed the polyamine concentration in tumour tissue taken from 10 cases of parotid carcinoma, noting a considerable increase in their levels compared to healthy control tissues. The hypothesis of being able to use the level of polyamines present in biological fluids in order to make an early diagnosis of tumours has now been definitively abandoned, both due to the scarce specificity and sensitivity of the available methods and due to the fact that increased polyamine concentrations were also found in physiological conditions and in the presence of non-tumour diseases; however, it is now being examined whether it would be possible to use polyamine levels to assess the degree of biochemical tumour malignancy or to evaluate the response to surgical or pharmacological treatment in patients with malignant tumours.
Asunto(s)
Neoplasias Faciales/química , Neoplasias Maxilomandibulares/química , Poliaminas/análisis , Carcinoma/química , Cromatografía Líquida de Alta Presión/métodos , Humanos , Neoplasias de la Parótida/química , Putrescina/análisis , Sensibilidad y Especificidad , Espermidina/análisis , Espermina/análisisRESUMEN
In vitro experimental evidence suggests tryptophan (TRP) is involved in protein modifications which could cause cataract formation in vivo. Previous studies of tryptophan plasma and serum metabolism are conflicting. In this study free and bound TRP plasma levels were measured in patients with senile cataract and in controls after an oral load of L-TRP (20 mg/kg b.w.). Free TRP levels were higher in patients than in controls one hour after L-TRP administration.
Asunto(s)
Catarata/sangre , Triptófano/sangre , Administración Oral , Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , Triptófano/farmacologíaRESUMEN
Serum free and total tryptophan levels have been measured in patients with cataracts and compared with the same levels in controls with clear lenses. No statistically significant differences have been demonstrated between the two groups of examined fasting subjects. Preliminary results seem to indicate that differences could be evident after L-tryptophan oral load.